{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:32:45Z","timestamp":1792989165777,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP J33C22002920006"],"award-info":[{"award-number":["CUP J33C22002920006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104882","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T02:26:08Z","timestamp":1754619968000},"page":"104882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic potential of lorlatinib in ALK-mutated metastatic paraganglioma: Insights from clinical case report and literature review"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3834-6122","authenticated-orcid":false,"given":"Maria Concetta","family":"Nigro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Corradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Di Dalmazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Tolento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arber","family":"Golemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"De Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Balacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vicennati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Abbondanza","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2025.104882_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104882_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 world health organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104882_bib3","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a european network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104882_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized Medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104882_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccell.2017.01.009","article-title":"Pheochromocytomas and paragangliomas, genetically diverse and minimalist, all at once!","volume":"31","author":"Dahia","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104882_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104882_bib7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the working group on endocrine hypertension of the european society of hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J. Hypertens."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104882_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/gs.2019.10.25","article-title":"Pheochromocytoma\/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options","volume":"9","author":"Antonio","year":"2020","journal-title":"Gland Surg."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104882_bib9","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104882_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114276","article-title":"Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: the phase 2 non-randomized SUTNET clinical trial","volume":"209","author":"Nasca","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104882_bib11","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104882_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104882_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The north American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104882_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2022.12.006","article-title":"Corrigendum to \"adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up\": [Annals of Oncology volume 31 (2020) 1476-1490]","volume":"34","author":"Fassnacht","year":"2023","journal-title":"Ann. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104882_bib15","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104882_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of High-Specific-Activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104882_bib17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE.","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104882_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68Ga-DOTA-Conjugated somatostatin Receptor-Targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J. Nucl. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104882_bib19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin. Endocrinol. (Oxf. )"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104882_bib20","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104882_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/1179554918763367","article-title":"Successful Second-Line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature","volume":"12","author":"Tena","year":"2018","journal-title":"Clin. Med Insights Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104882_bib22","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of Pheochromocytoma\/Paraganglioma: a guide for the practicing clinician in the era of precision Medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104882_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier","year":"2012","journal-title":"Endocr. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104882_bib24","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104882_bib25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104882_bib26","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/cancers11040436","article-title":"Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies","volume":"11","author":"Pang","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104882_bib27","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/cancers11050654","article-title":"The significant reduction or complete eradication of subcutaneous and metastatic lesions in a pheochromocytoma mouse model after immunotherapy using Mannan-BAM, TLR ligands, and Anti-CD40","volume":"11","author":"Caisova","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104882_bib28","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1210\/clinem\/dgac471","article-title":"Targeted therapies in pheochromocytoma and paraganglioma","volume":"107","author":"Wang","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104882_bib29","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1523\/JNEUROSCI.4243-10.2011","article-title":"Frizzled3 is required for neurogenesis and target innervation during sympathetic nervous system development","volume":"31","author":"Armstrong","year":"2011","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104882_bib30","doi-asserted-by":"crossref","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104882_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00441-017-2784-8","article-title":"The ALK receptor in sympathetic neuron development and neuroblastoma","volume":"372","author":"Janoueix-Lerosey","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104882_bib32","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/cancers14071650","article-title":"Anaplastic large cell lymphoma: molecular pathogenesis and treatment","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104882_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104882_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104882_bib35","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med Chem."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104882_bib36","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104882_bib37","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104882_bib38","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line lorlatinib or crizotinib in advanced alk-Positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"7215","key":"10.1016\/j.critrevonc.2025.104882_bib39","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Moss\u00e9","year":"2008","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104882_bib40","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00595-019-01790-0","article-title":"The roles played by the MYCN, trk, and ALK genes in neuroblastoma and neural development","volume":"49","author":"Higashi","year":"2019","journal-title":"Surg. Today"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104882_bib41","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1158\/0008-5472.CAN-10-4041","article-title":"Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene","volume":"71","author":"Murugan","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104882_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1593\/neo.81040","article-title":"Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK","volume":"11","author":"Grzelinski","year":"2009","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104882_bib43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.37.8588","article-title":"Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications","volume":"30","author":"van Gaal","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104882_bib44","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104882_bib45","doi-asserted-by":"crossref","first-page":"23715","DOI":"10.18632\/oncotarget.8173","article-title":"TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors","volume":"7","author":"Amin","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104882_bib46","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/1878-0261.13446","article-title":"EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries","volume":"17","author":"Elshatlawy","year":"2023","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104882_bib47","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41467-021-21396-w","article-title":"Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer","volume":"12","author":"Mizuta","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104882_bib48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2014.05.020","article-title":"Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance","volume":"351","author":"Kodama","year":"2014","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104882_bib49","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/molecules23071610","article-title":"Molecular modeling for structural insights concerning the activation mechanisms of F1174L and R1275Q mutations on anaplastic lymphoma kinase","volume":"23","author":"Jiang","year":"2018","journal-title":"Molecules"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104882_bib50","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","article-title":"The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers","volume":"70","author":"Sasaki","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104882_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100233","volume":"6","author":"Heregger","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104882_bib52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10555-020-09843-4","article-title":"Genetic predisposition and chromosome instability in neuroblastoma","volume":"39","author":"Tonini","year":"2020","journal-title":"Cancer Metastas.. Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104882_bib53","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med Res Rev."},{"key":"10.1016\/j.critrevonc.2025.104882_bib54","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104882_bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrc1014","article-title":"Neuroblastoma: biological insights into a clinical enigma","volume":"3","author":"Brodeur","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104882_bib56","first-page":"1032","article-title":"Neuroblastoma and ganglioneuroma in a child with multiple neurofibromatosis","volume":"19","author":"Knudson","year":"1966","journal-title":"Implic. Mutat. Orig. neuroblastoma. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104882_bib57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.suc.2022.04.007","article-title":"Benign neurogenic tumors","volume":"102","author":"Farma","year":"2022","journal-title":"Surg. Clin. North Am."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104882_bib58","doi-asserted-by":"crossref","first-page":"12056","DOI":"10.3390\/ijms252212056","article-title":"Novel gene variants in a nationwide cohort of patients with pheochromocytoma and paraganglioma","volume":"25","author":"Mart\u00ednez de Lapiscina","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104882_bib59","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.2147\/DDDT.S147384","article-title":"Entrectinib and other ALK\/TRK inhibitors for the treatment of neuroblastoma","volume":"12","author":"Pacenta","year":"2018","journal-title":"Drug Des. Devel Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104882_bib60","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1440-1681.2008.04881.x","article-title":"Recent advances in the genetics of phaeochromocytoma and functional paraganglioma","volume":"35","author":"Gimenez-Roqueplo","year":"2008","journal-title":"Clin. Exp. Pharm. Physiol."},{"issue":"7215","key":"10.1016\/j.critrevonc.2025.104882_bib61","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","article-title":"Oncogenic mutations of ALK kinase in neuroblastoma","volume":"455","author":"Chen","year":"2008","journal-title":"Nature"},{"issue":"7215","key":"10.1016\/j.critrevonc.2025.104882_bib62","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature07397","article-title":"Activating mutations in ALK provide a therapeutic target in neuroblastoma","volume":"455","author":"George","year":"2008","journal-title":"Nature"},{"issue":"7215","key":"10.1016\/j.critrevonc.2025.104882_bib63","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature07398","article-title":"Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma","volume":"455","author":"Janoueix-Lerosey","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104882_bib64","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","article-title":"ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma","volume":"26","author":"Bresler","year":"2014","journal-title":"Cancer Cell"},{"issue":"108","key":"10.1016\/j.critrevonc.2025.104882_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002950","article-title":"Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma","volume":"3","author":"Bresler","year":"2011","journal-title":"Sci. Transl. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104882_bib66","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/cancers15030560","article-title":"Therapeutic targeting of ALK in neuroblastoma: experience of Italian precision Medicine in pediatric oncology","volume":"15","author":"Pastorino","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104882_bib67","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1158\/1078-0432.CCR-24-0753","article-title":"Sequential analysis of cfDNA reveals clonal evolution in patients with neuroblastoma receiving ALK-Targeted therapy","volume":"30","author":"Bobin","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104882_bib68","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-11-1648","article-title":"ALK mutations conferring differential resistance to structurally diverse ALK inhibitors","volume":"17","author":"Heuckmann","year":"2011","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104882_bib69","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential alk inhibitors can select for Lorlatinib-Resistant compound alk mutations in alk-Positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104882_bib70","doi-asserted-by":"crossref","first-page":"a006064","DOI":"10.1101\/mcs.a006064","article-title":"Exceptional response to the alk and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed alk F1174L-mutated neuroblastoma","volume":"7","author":"Liu","year":"2021","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.critrevonc.2025.104882_bib71","article-title":"Anaplastic lymphoma kinase inhibitors for therapy of neuroblastoma in adults","volume":"7","author":"Stiefel","year":"2023","journal-title":"JCO Precis Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104882_bib72","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41591-023-02297-5","article-title":"Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results","volume":"29","author":"Goldsmith","year":"2023","journal-title":"Nat. Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:33:52Z","timestamp":1792985632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":72,"alternative-id":["S1040842825002707"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104882","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of lorlatinib in ALK-mutated metastatic paraganglioma: Insights from clinical case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104882"}}